Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (MyocetÂ®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to study the feasibility of R-COMP in this cohort of patients.
Diffuse Large B-Cell Lymphoma
DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Prednisone|DRUG: Doxorubicin
Feasibility of R-COMP in cardiopathic patients, 2 years
Response rates, 1 year|Progression free survival, 2 years|Overall Survival, 3 years
This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to study the feasibility of R-COMP in this cohort of patients.